PENNSYLVANIA
Johnson & Johnson Agrees to Fraud Resolution
On Nov. 4, the DOJ announced that it had reached an agreement with pharmaceutical manufacturer Johnson & Johnson (J&J) and its subsidiaries to resolve multiple health care fraud investigations (state and federal) relating to Invenga, Natrecor, and Risperdal, prescription drugs manufactured by the company.
This premium content is locked for Business Crimes Bulletin subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN Business Crimes Bulletin
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.